NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03709316,A Study of ZL-2306 (Niraparib) as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer,https://clinicaltrials.gov/study/NCT03709316,,UNKNOWN,"Niraparib is a PARP inhibitor. This is a 2:1 randomized, double-blind, placebo-controlled study conducted in patients with advanced (FIGO Stage III or IV) ovarian cancer to evaluate Efficacy and Safety of ZL-2306 (Niraparib) for Maintenance Treatment",NO,Ovarian Cancer,DRUG: ZL-2306 (Nirapairb)|DRUG: Placebo Comparator,"BICR-assessed progression-free survival (PFS), the time from randomization to progressive disease or death due to various causes assessed by the BICR according to RECIST 1.1, whichever occurs first, Approximately 36 months since the first subject enrolled","Overall survival (OS), the time from the date of randomization to the date of death caused by any reason., Approximately 36 months since the first subject enrolled|Time to first subsequent anti-tumor treatment (TFST), the time from the date of randomization in the study to the date when the first subsequent anti-tumor treatment starts, Approximately 36 months since the first subject enrolled|PFS and OS assessed by BICR in patients with HRD (homologous recombination defects), positive patient population (including gBRCA-positive patients)., Approximately 36 months since the first subject enrolled",,"Zai Lab (Shanghai) Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE3,384,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",ZL-2306-004,2018-06-30,2022-01-29,2023-12-30,2018-10-17,,2021-06-02,"Anhui Provincal Hospital, Hefei, Anhui, China|Chongqing Cancer Hospital, Chongqing, Chongqing, China|Fujian Cancer Hospital, Fuzhou, Fujian, China|Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China|The first affiliated hospital, Sun Yat-sen University, Guangzhou, Guangdong, China|Guizhou Cancer hospital, Guiyang, Guizhou, China|Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China|Henan Cancer Hospital, Zhengzhou, Henan, China|Hubei Cancer Hospital, Wuhan, Hubei, China|Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China|Zhongnan hospital of wuhan university, Wuhan, Hubei, China|Hunan Cancer Hospital, Changsha, Hunan, China|Xiangya Hospital Central South Hospital, Changsha, Hunan, China|Jiangsu Cancer Hospital, Nanjing, Jiangsu, China|The First Hospital of Jilin University, Changchun, Jilin, China|Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China|Qilu Hospital of Shandong University, Jinan, Shandong, China|second hospital of Shanxi medical university, Taiyuan, Shanxi, China|West China second university hospital, Chengdu, Sichuan, China|Tianjin Central Hospital of Gynecology Obstetrics, Tianjin, Tianjin, China|Affiliate Cancer Hospital Xinjiang Medical University, Urumqi, Xinjiang, China|Yunnan Cancer Hospital, Kunming, Yunnan, China|Woman's hospital School of medicine Zhejiang University, Hangzhou, Zhejiang, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China|the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China|Beijing Cancer Hospital, Beijing, China|Cancer Hospital of Chinese Academy of Medical Sciences, Beijing, China|Peking Union Medical College Hospital, Beijing, China|Peking University People's hospital, Beijing, China|Fudan University Shanghai Cancer Center, Shanghai, China|Tianjin Tumour Hospital, Tianjin, China",
